- Home
- MGNX vs NBTX Comparison
MGNX vs NBTX Comparison
Compare MGNX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NBTX
- Stock Information
- Founded
- MGNX 2000
- NBTX 2003
- Country
- MGNX United States
- NBTX France
- Employees
- MGNX N/A
- NBTX N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- NBTX Health Care
- Exchange
- MGNX Nasdaq
- NBTX Nasdaq
- Market Cap
- MGNX 202.7M
- NBTX 201.9M
- IPO Year
- MGNX 2013
- NBTX 2020
- Fundamental
- Price
- MGNX $2.86
- NBTX $3.46
- Analyst Decision
- MGNX Hold
- NBTX Strong Buy
- Analyst Count
- MGNX 10
- NBTX 1
- Target Price
- MGNX $7.17
- NBTX $12.00
- AVG Volume (30 Days)
- MGNX 642.4K
- NBTX 20.4K
- Earning Date
- MGNX 03-06-2025
- NBTX 09-18-2024
- Dividend Yield
- MGNX N/A
- NBTX N/A
- EPS Growth
- MGNX N/A
- NBTX N/A
- EPS
- MGNX N/A
- NBTX N/A
- Revenue
- MGNX $141,329,000.00
- NBTX $45,220,186.00
- Revenue This Year
- MGNX $174.73
- NBTX N/A
- Revenue Next Year
- MGNX N/A
- NBTX N/A
- P/E Ratio
- MGNX N/A
- NBTX N/A
- Revenue Growth
- MGNX 16.68
- NBTX 526.17
- 52 Week Low
- MGNX $2.79
- NBTX $2.76
- 52 Week High
- MGNX $21.88
- NBTX $7.65
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- NBTX 59.78
- Support Level
- MGNX $2.93
- NBTX $3.40
- Resistance Level
- MGNX $3.16
- NBTX $3.64
- Average True Range (ATR)
- MGNX 0.18
- NBTX 0.10
- MACD
- MGNX -0.02
- NBTX 0.05
- Stochastic Oscillator
- MGNX 1.90
- NBTX 75.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.